French pharmaceutical giant Sanofi Pasteur on Friday (July 11) announced the publication in the medical journal The Lancet detailed results of its first landmark phase III dengue vaccine efficacy study that could pave the way to combating the mosquito-borne virus that sickens millions every year.
